Regulus Therapeutics マネジメント

マネジメント基準チェック /24

Regulus Therapeuticsの CEO はJay Haganで、 May2017年に任命され、の在任期間は 7.5年です。の年間総報酬は$ 2.57Mで、 23.9%給与と76.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.087%を直接所有しており、その価値は$ 79.95K 。経営陣と取締役会の平均在任期間はそれぞれ5.3年と7.5年です。

主要情報

Jay Hagan

最高経営責任者

US$2.6m

報酬総額

CEO給与比率	23.9%
CEO在任期間	7.5yrs
CEOの所有権	0.09%
経営陣の平均在職期間	5.3yrs
取締役会の平均在任期間	7.5yrs

経営陣の近況

Recent updates

Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth

Sep 28

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Jun 09

Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease

May 03

Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Mar 13

Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Mar 10

Regulus Therapeutics announces closing of $19.4M private placement

Dec 08

Regulus Therapeutics EPS beats by $0.17, beats on revenue

Nov 05

CEO報酬分析

Regulus Therapeutics の収益と比較して、Jay Hagan の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$42m
Jun 30 2024	n/a	n/a	-US$35m
Mar 31 2024	n/a	n/a	-US$31m
Dec 31 2023	US$3m	US$616k	-US$30m
Sep 30 2023	n/a	n/a	-US$29m
Jun 30 2023	n/a	n/a	-US$28m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$1m	US$598k	-US$28m
Sep 30 2022	n/a	n/a	-US$29m
Jun 30 2022	n/a	n/a	-US$30m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	US$2m	US$568k	-US$28m
Sep 30 2021	n/a	n/a	-US$22m
Jun 30 2021	n/a	n/a	-US$15m
Mar 31 2021	n/a	n/a	-US$16m
Dec 31 2020	US$2m	US$552k	-US$16m
Sep 30 2020	n/a	n/a	-US$19m
Jun 30 2020	n/a	n/a	-US$23m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	US$2m	US$536k	-US$19m
Sep 30 2019	n/a	n/a	-US$22m
Jun 30 2019	n/a	n/a	-US$27m
Mar 31 2019	n/a	n/a	-US$36m
Dec 31 2018	US$2m	US$520k	-US$49m
Sep 30 2018	n/a	n/a	-US$55m
Jun 30 2018	n/a	n/a	-US$60m
Mar 31 2018	n/a	n/a	-US$68m
Dec 31 2017	US$2m	US$475k	-US$72m

報酬と市場: Jayの総報酬 ($USD 2.57M ) は、 US市場 ($USD 650.80K ) の同規模の企業の平均を上回っています。

報酬と収益: Jayの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Jay Hagan (55 yo)

7.5yrs

在職期間

US$2,574,323

報酬

Mr. Joseph P. Hagan, also known as Jay, served as Independent Director of Zosano Pharma Corporation since May 22, 2015, until May 10, 2022. He has been the Chief Executive Officer and Director of Regulus T...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Joseph Hagan	CEO & Director	7.5yrs	US$2.57m	0.087% $ 80.0k
Crispina Calsada	Chief Financial Officer	5.3yrs	US$1.07m	0.0088% $ 8.1k
Christopher Aker	Senior VP	13.8yrs	US$1.09m	0.015% $ 14.1k
Preston Klassen	President	1.4yrs	データなし	0% $ 0
Daniel Penksa	VP of Finance & Controller	5.3yrs	データなし	データなし
Claire Padgett	Senior Vice President of Clinical Operations	2yrs	データなし	データなし
Rekha Garg	Chief Medical Officer	2yrs	データなし	データなし
Edmund Lee	Vice President of Translational Medicine	no data	データなし	データなし

5.3yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: RGLSの経営陣は経験豊富で経験豊富です（平均在職期間は5.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Joseph Hagan	CEO & Director	7.5yrs	US$2.57m	0.087% $ 80.0k
Preston Klassen	President	1.4yrs	データなし	0% $ 0
William Rastetter	Independent Director	11.6yrs	US$99.44k	0.060% $ 54.7k
Timothy Wright	Member of the Scientific Advisory Board	5.7yrs	US$1.48m	データなし
Stelios Papadopoulos	Independent Chairman of the Board	15.8yrs	US$131.44k	1.49% $ 1.4m
David Baltimore	Chairman of the Scientific Advisory Board & Independent Director	15.8yrs	US$95.44k	0.0039% $ 3.6k
Jason Nunn	Independent Director	5.4yrs	US$97.44k	0% $ 0
Thomas Tuschl	Member of the Scientific Advisory Board	no data	データなし	データなし
Markus Stoffel	Member of the Scientific Advisory Board	no data	データなし	データなし
Hugh Rosen	Independent Director	8.4yrs	US$93.44k	0.0027% $ 2.5k
Kathryn Collier	Independent Director	6.6yrs	US$107.44k	0.010% $ 9.4k
Pascale Witz	Independent Director	7.4yrs	US$93.44k	0.0072% $ 6.6k

7.5yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: RGLSの取締役会は経験豊富であると考えられます ( 7.5年の平均在任期間)。

Regulus Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Regulus Therapeutics Inc. Announces Promotion of Rekha Garg to Chief Medical Officer

Regulus Therapeutics Inc., Annual General Meeting, May 16, 2024

Insufficient new directors

Regulus Therapeutics Inc. Appoints Preston S. Klassen to President and Head of Research and Development

Regulus Therapeutics Inc. Announces Resignation of Simos Simeonidis as Board Member

Regulus Therapeutics Inc. Announces Executive Changes

Recent updates

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Rgls8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease

Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth

New minor risk - Profitability

New minor risk - Market cap size

Price target increased by 49% to US$11.00

Regulus Therapeutics Inc. Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration

Regulus Therapeutics Inc. Announces Promotion of Rekha Garg to Chief Medical Officer

Regulus Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Regulus Therapeutics Inc., Annual General Meeting, May 16, 2024

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors

Regulus Therapeutics Inc. announced that it expects to receive $100 million in funding from a group of investors

Insufficient new directors

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1B Multiple Ascending Dose (Mad) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (Madpkd)

New major risk - Financial position

Regulus Therapeutics, Inc. Announces First Patient Dosed in Second Cohort of Phase 1b Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Appoints Preston S. Klassen to President and Head of Research and Development

Regulus Therapeutics Advances to Cohort 2 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces Resignation of Simos Simeonidis as Board Member

Regulus Therapeutics Inc. Announces Executive Changes

Insufficient new directors

Regulus Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022

Regulus Therapeutics Inc. Announces First Patient Dosed in Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces Positive Topline Safety and Pharmacokinetic Data from the Phase 1 Single-Ascending Dose (Sad) Clinical Trial of Rgls8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus surges 15% after Phase 1 data for kidney disease candidate

Price target increased to US$20.00

Regulus Therapeutics GAAP loss per share narrows

Regulus Therapeutics Inc. to Report Q2, 2022 Results on Aug 11, 2022

Insufficient new directors

Price target increased to US$20.00

Insufficient new directors

Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. Announces FDA Acceptance of Investigational New Drug Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. to Report Q1, 2022 Results on May 12, 2022

Price target increased to US$1.50

Full year 2021 earnings: EPS misses analyst expectations

Regulus Therapeutics Inc. to Report Q4, 2021 Results on Mar 10, 2022

Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome

Regulus Therapeutics Inc. Announces Successful Completion of Pre-Ind Meeting with FDA for Rgls8429

Regulus Therapeutics Inc. announced that it has received $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc.

Regulus Therapeutics Inc. announced that it expects to receive $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc.

Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Consensus forecasts updated

The Read On Regulus Therapeutics

Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021

Regulus Therapeutics Inc. to Present Additional Data from Its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program At PKD Connect 2021

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Regulus Therapeutics Inc. Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease Program

Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease

Analysts update estimates

Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Full year 2020 earnings released: US$0.45 loss per share (vs US$1.08 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

New 90-day high: US$1.94

Regulus Therapeutics Inc. Announces Completion of Enrollment in First Cohort of Phase 1B Clinical Trial of Rgls4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Appoints Alice S. Huang to the Board of Directors

New 90-day high: US$1.55

New 90-day high: US$1.21

Regulus Therapeutics announces closing of $19.4M private placement

マネジメント基準チェック /24